MA38323B1 - Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale - Google Patents

Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale

Info

Publication number
MA38323B1
MA38323B1 MA38323A MA38323A MA38323B1 MA 38323 B1 MA38323 B1 MA 38323B1 MA 38323 A MA38323 A MA 38323A MA 38323 A MA38323 A MA 38323A MA 38323 B1 MA38323 B1 MA 38323B1
Authority
MA
Morocco
Prior art keywords
amelioration
prevention
treatment
viral disease
pyrimidone derivatives
Prior art date
Application number
MA38323A
Other languages
English (en)
Other versions
MA38323A1 (fr
Inventor
Zhuming Zhang
Achyutharao Sidduri
Andrea Wolkerstorfer
Oliver Szolar
Norbert Handler
Helmut Buschmann
Stephen Cusack
Mark Smith
Sung-Sau So
Ronald Charles Hawley
Original Assignee
Hoffmann La Roche
Savira Pharmaceuticals Gmbh
European Molecular Biology Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50070507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38323(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Savira Pharmaceuticals Gmbh, European Molecular Biology Laboratory filed Critical Hoffmann La Roche
Publication of MA38323A1 publication Critical patent/MA38323A1/fr
Publication of MA38323B1 publication Critical patent/MA38323B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un composé de formule générale (i), éventuellement sous la forme d'un sel, solvate, polymorphe, comédicament, cocristal, promédicament, tautomère, racémique, énantiomère ou diastéréoisomère pharmaceutiquement acceptable ou d'un mélange de ceux-ci, qui sont utiles dans le traitement, l'amélioration ou la prévention d'une maladie virale. De plus, l'invention concerne des polythérapies spécifiques.
MA38323A 2013-01-08 2014-01-07 Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale MA38323B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750017P 2013-01-08 2013-01-08
PCT/EP2014/050165 WO2014108406A1 (fr) 2013-01-08 2014-01-07 Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale

Publications (2)

Publication Number Publication Date
MA38323A1 MA38323A1 (fr) 2017-02-28
MA38323B1 true MA38323B1 (fr) 2018-05-31

Family

ID=50070507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38323A MA38323B1 (fr) 2013-01-08 2014-01-07 Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale

Country Status (21)

Country Link
US (1) US9045486B2 (fr)
EP (1) EP2943495B1 (fr)
JP (1) JP2016518305A (fr)
KR (1) KR20150103285A (fr)
CN (1) CN104918942A (fr)
AR (1) AR094378A1 (fr)
AU (1) AU2014204889A1 (fr)
BR (1) BR112015012693A2 (fr)
CA (1) CA2894642A1 (fr)
CL (1) CL2015001916A1 (fr)
CR (1) CR20150337A (fr)
EA (1) EA201591291A1 (fr)
HK (2) HK1211286A1 (fr)
IL (1) IL239656A0 (fr)
MA (1) MA38323B1 (fr)
MX (1) MX2015008293A (fr)
PE (1) PE20151722A1 (fr)
PH (1) PH12015501517A1 (fr)
SG (1) SG11201503946UA (fr)
TW (1) TW201443053A (fr)
WO (1) WO2014108406A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
JP6448647B2 (ja) 2013-09-12 2019-01-09 アリオス バイオファーマ インク． アザ−ピリドン化合物およびその用途
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
AU2016229147C1 (en) 2015-03-11 2021-03-25 Janssen Biopharma, Inc. Aza-pyridone compounds and uses thereof
US10392406B2 (en) 2015-04-28 2019-08-27 Shionogi & Co., Ltd. Substituted polycyclic pyridone derivatives and prodrugs thereof
ES2938877T3 (es) 2015-04-28 2023-04-17 Shionogi & Co Derivados de piridona policíclicos sustituidos y profármacos de los mismos
TW201726678A (zh) 2015-10-30 2017-08-01 赫孚孟拉羅股份公司 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途
CA3008607A1 (fr) 2015-12-15 2017-06-22 Shionogi & Co., Ltd. Medicament pour traiter la grippe caracterise en ce qu'il comprend une combinaison d'un inhibiteur d'endonuclease coiffe-dependante avec un medicament antigrippal
WO2017109088A1 (fr) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Dérivés pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale
JP6918819B2 (ja) 2016-03-08 2021-08-11 ノバルティス アーゲー オルトミクソウイルス感染の処置に有用な三環式化合物
WO2017158147A1 (fr) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Dérivés de pyrimidone et leur utilisation pour le traitement, la prévention ou l'atténuation des symptômes d'une maladie virale
WO2017158151A1 (fr) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Dérivés de pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale
JP6961963B2 (ja) * 2016-04-01 2021-11-05 三菱ケミカル株式会社 フルフラールの製造方法
EP3458455B1 (fr) * 2016-05-20 2021-06-16 F. Hoffmann-La Roche AG Nouveaux composés de pyrazine ayant un coupleur d'oxygène, de soufre et d'azote pour le traitement de maladies infectieuses
SG10201913616UA (en) 2016-05-31 2020-03-30 Kalvista Pharmaceuticals Ltd Pyrazole derivatives as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
MA45939A (fr) 2016-08-10 2019-06-19 Shionogi & Co Dérivé de pyridone polycyclique substitué et composition pharmaceutique contenant un promédicament de celui-ci
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
US11234939B2 (en) 2017-11-29 2022-02-01 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
CR20200372A (es) 2018-02-28 2020-10-26 Novartis Ag Derivados de 10-(di(fenil)metil)-4-hidroxi8,9,9a,10-tetrahidro-7h-pirrolo (1`, 2`:4-5) pirazino (1,2-b) piridazina-3, 5-diona y compuestos relacionados como inhibidores de la replicación del ortomixo virus para el tratamiento de la influenza
WO2021028645A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
US20240228495A1 (en) * 2020-03-25 2024-07-11 Sri International Tricyclic Inhibitors of Influenza Virus Endonuclease
EP4074317A1 (fr) 2021-04-14 2022-10-19 Bayer AG Dérivés de phosphore en tant que nouveaux inhibiteurs de sos1
WO2024061300A1 (fr) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibiteurs de trex1 et utilisations associées
US20240199558A1 (en) 2022-10-19 2024-06-20 Astrazeneca Ab 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx3cr1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
CN1930161A (zh) * 2004-03-09 2007-03-14 P·安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
CN101014572B (zh) 2004-09-15 2011-07-06 盐野义制药株式会社 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物
WO2006125048A2 (fr) 2005-05-16 2006-11-23 Gilead Sciences, Inc. Composes inhibant l'integrase
AU2006272521A1 (en) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
EP2412708A4 (fr) 2009-03-26 2014-07-23 Shionogi & Co Dérivé de 3-hydroxy-4-pyridone substitué
TWI520959B (zh) 2009-06-15 2016-02-11 鹽野義製藥股份有限公司 經取代的多環胺甲醯吡啶酮衍生物及其用途
WO2011000566A2 (fr) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Composés et compositions pharmaceutiques pour le traitement de d’infections virales à arn simple brin, sens négatif
JP5553393B2 (ja) 2010-09-24 2014-07-16 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体のプロドラッグ

Also Published As

Publication number Publication date
SG11201503946UA (en) 2015-09-29
CN104918942A (zh) 2015-09-16
AU2014204889A1 (en) 2015-06-11
HK1211286A1 (en) 2016-05-20
CL2015001916A1 (es) 2016-01-22
EP2943495B1 (fr) 2016-12-28
IL239656A0 (en) 2015-08-31
BR112015012693A2 (pt) 2017-07-11
AR094378A1 (es) 2015-07-29
PE20151722A1 (es) 2015-11-19
EP2943495A1 (fr) 2015-11-18
PH12015501517A1 (en) 2015-11-09
EA201591291A1 (ru) 2015-12-30
CA2894642A1 (fr) 2014-07-17
HK1212686A1 (zh) 2016-06-17
JP2016518305A (ja) 2016-06-23
MA38323A1 (fr) 2017-02-28
US9045486B2 (en) 2015-06-02
MX2015008293A (es) 2016-06-02
KR20150103285A (ko) 2015-09-09
US20140194431A1 (en) 2014-07-10
WO2014108406A1 (fr) 2014-07-17
CR20150337A (es) 2015-11-02
TW201443053A (zh) 2014-11-16

Similar Documents

Publication Publication Date Title
MA38323B1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MX2014014109A (es) Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
MA37405A1 (fr) Composés hétérocyclyle
PH12016500359A1 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
MY166866A (en) Heterocyclic derivative and pharmaceutical drug
WO2008094909A3 (fr) Composés de quinazolinone et de pyrimidinone fusionnés et leur utilisation dans le traitement de maladies ou d'affections induites par les canaux sodiques
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
MA38138A1 (fr) Dérivés inédits de quinolone
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA201491283A1 (ru) Ингибитор регулирующей апоптотические сигналы киназы
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
JP2019524883A5 (fr)
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MX342176B (es) Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2015008288A (es) Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
TN2017000158A1 (en) Carbazole derivatives
MX2014003803A (es) Derivados de acido heteroarilo hidroxamico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MA39983B1 (fr) Dérivés de carboxamide
WO2008109856A3 (fr) Procédés de traitement de maladies ou d'affections associées aux canaux à sodium au moyen de composés de type diazépinone.